Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Pembrolizumab plus mFOLFOX7 of FOLFIRI bij MSS/MMR-proficiënt mCRC
okt 2024 | Immuuntherapie, Maag-darm-leveroncologie